<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPJ</journal-id>
<journal-id journal-id-type="hwp">spcpj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Pediatr (Phila)</journal-id>
<journal-title>Clinical Pediatrics</journal-title>
<issn pub-type="ppub">0009-9228</issn>
<issn pub-type="epub">1938-2707</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0009922813482751</article-id>
<article-id pub-id-type="publisher-id">10.1177_0009922813482751</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Usefulness of Urinary Immune Biomarkers in the Evaluation of Neonatal Sepsis</article-title>
<subtitle>A Pilot Project</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Suguna Narasimhulu</surname><given-names>Sukumar</given-names></name>
<degrees>MD, MPH</degrees>
<xref ref-type="aff" rid="aff1-0009922813482751">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hendricks-Muñoz</surname><given-names>Karen D.</given-names></name>
<degrees>MD, MPH</degrees>
<xref ref-type="aff" rid="aff1-0009922813482751">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Borkowsky</surname><given-names>William</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922813482751">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mally</surname><given-names>Pradeep</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922813482751">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0009922813482751"><label>1</label>New York University, New York, NY, USA</aff>
<author-notes>
<corresp id="corresp1-0009922813482751">Sukumar Suguna Narasimhulu, New York University, 160 East 32nd Street, L-3 Medical, New York, NY 10016, USA. Email: <email>snsukumar@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>52</volume>
<issue>6</issue>
<fpage>520</fpage>
<lpage>526</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><italic>Objective</italic>. Our hypothesis is that specific proinflammatory and anti-inflammatory urinary cytokines are useful in the diagnostic evaluation of risk for sepsis in term neonates. We conducted a pilot, prospective hospital-based longitudinal observational study to test the urine of term neonates with a 13 biomarker panel of cytokines. <italic>Methods</italic>. Infants were divided into 2 groups: The control group (n = 15) consisted of infants admitted to newborn nursery, and the test group (n = 15) consisted of infants admitted to the neonatal intensive care unit for presumed sepsis. Bagged urine samples were collected from 30 term neonates for testing our hypothesis. <italic>Results</italic>. Urinary interleukin (IL)-8 (<italic>P</italic> = .004*), inducible protein (IP)-10 (<italic>P</italic> = .007*), and monocyte chemoattractant protein (MCP)-1 (<italic>P</italic> = .02) were significantly increased in the test group compared with the control group. <italic>Conclusions</italic>. Urinary IL-8, IP-10, and MCP-1 are proinflammatory cytokines that are increased in the neonate during an infectious inflammatory process. These may be useful predictors as an adjunct to the current protocols to recognize neonatal sepsis.</p>
</abstract>
<kwd-group>
<kwd>urinary cytokines</kwd>
<kwd>biomarkers</kwd>
<kwd>neonatal sepsis</kwd>
<kwd>sepsis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0009922813482751" sec-type="intro">
<title>Introduction</title>
<p>Early, accurate, and rapid diagnosis of neonatal sepsis is a major diagnostic challenge in neonatology.<sup><xref ref-type="bibr" rid="bibr1-0009922813482751">1</xref></sup> Early-onset sepsis is defined as isolation of bacterial pathogens from a blood culture and/or cerebrospinal fluid culture obtained within the first 3 days of life, as defined by both the Vermont Oxford Network and National Institute of Child Health and Human Development.<sup><xref ref-type="bibr" rid="bibr2-0009922813482751">2</xref></sup> The incidence of culture-proven sepsis is approximately 2 per 1000 live births,<sup><xref ref-type="bibr" rid="bibr3-0009922813482751">3</xref></sup> and of the 7% to 13% of neonates who are evaluated for neonatal sepsis, only 3% to 8% have culture-proven sepsis.<sup><xref ref-type="bibr" rid="bibr3-0009922813482751">3</xref></sup> The diagnosis of sepsis in a newborn infant is difficult, both because of nonspecific clinical presentation and lack of reliable diagnostic tests.<sup><xref ref-type="bibr" rid="bibr3-0009922813482751">3</xref><xref ref-type="bibr" rid="bibr4-0009922813482751"/><xref ref-type="bibr" rid="bibr5-0009922813482751"/><xref ref-type="bibr" rid="bibr6-0009922813482751"/><xref ref-type="bibr" rid="bibr7-0009922813482751"/>-<xref ref-type="bibr" rid="bibr8-0009922813482751">8</xref></sup> The current gold standard for diagnosing bacteremia is by culturing a blood sample, and this is found to be suboptimal in newborn infants because only 25% to 54% of cultures are positive in diagnosing bacteremia, and it takes an average of 1 to 2 days for the interpretation of these results.<sup><xref ref-type="bibr" rid="bibr9-0009922813482751">9</xref></sup></p>
<p>Because of the lack of a quick, optimal, reliable diagnostic test to corroborate bacteremia, antimicrobial therapy is started in infants even with the slightest clinical suspicion of infection. This approach may be helpful in combating acute infection at the expense of increased risk of drug side effects and the emergence of drug-resistant organisms. In recent years, there has been a great interest in identifying potential immunological surrogate biomarkers for diagnosis of infection.<sup><xref ref-type="bibr" rid="bibr9-0009922813482751">9</xref></sup> An ideal biomarker has to be sensitive and specific, have a quick turnaround time, and be easily accessible, and testing for it should be noninvasive.<sup><xref ref-type="bibr" rid="bibr10-0009922813482751">10</xref></sup></p>
<p>Neonatal sepsis is a pathogen-initiated but cytokine-mediated condition in which immune, inflammatory, and coagulation homeostasis is altered.<sup><xref ref-type="bibr" rid="bibr11-0009922813482751">11</xref></sup> The evolution of disease and clinical symptoms are dependent on a complex and delicate balance between the proinflammatory and anti-inflammatory factors and multiple-function cytokines, based on their final effect on the immune system. Cytokines are multifunctional pleiotropic proteins that play crucial roles in cell-to cell communication, cellular activation, and neonatal sepsis.<sup><xref ref-type="bibr" rid="bibr12-0009922813482751">12</xref>,<xref ref-type="bibr" rid="bibr13-0009922813482751">13</xref></sup></p>
<p>Functionally, cytokines have been classified as being either proinflammatory (Th1-type, stimulatory), anti-inflammatory (Th2-type, inhibitory), or multifunction depending on the final balance of their effects on the immune system. The proinflammatory cytokines—interferon γ (IFNγ), tumor necrosis factor α (TNFα), inducible protein (IP)-10, interleukin (IL)-2, IL-6, IL-8, IL-12, and IL-17—multiple function inflammatory cytokines—IL-1β, monocyte chemoattractant protein (MCP)-1, and sCD40L (soluble CD40 ligand)—and growth factors (IL-3, colony-stimulating factors) and their secondary mediators, including nitric oxide, thromboxanes, leukotrienes, platelet-activating factor, prostaglandins, and complement, cause activation of the coagulation cascade, the complement cascade, and the production of prostaglandins, leukotrienes, proteases, and oxidants.</p>
<p>Most adverse effects of sepsis, such as systemic inflammatory response syndrome, disseminated intravascular coagulation, septic shock, multiple organ dysfunction syndrome, and complement-activated response syndrome, are strictly associated with the imbalance between production of proinflammatory mediators<sup><xref ref-type="bibr" rid="bibr14-0009922813482751">14</xref><xref ref-type="bibr" rid="bibr15-0009922813482751"/><xref ref-type="bibr" rid="bibr16-0009922813482751"/>-<xref ref-type="bibr" rid="bibr17-0009922813482751">17</xref></sup> and anti-inflammatory cytokines, such as IL-4, IL-10, TNFsr, IL-1ra, and transforming growth factor-β2.</p>
<p>Research has focused on other body fluids as diagnostic biomarkers, testing for cytokines for neonatal sepsis using maternal and neonatal serum, infant tracheal aspirate, amniotic fluid, and cord blood. Urinary cytokines have been shown to be useful as prognostic biomarkers in adult diseases such as carcinoma of the bladder<sup><xref ref-type="bibr" rid="bibr18-0009922813482751">18</xref></sup> and HIV-associated wasting.<sup><xref ref-type="bibr" rid="bibr19-0009922813482751">19</xref></sup> They have not been explored as biomarkers of neonatal sepsis syndrome. Thus, our hypothesis was that specific proinflammatory and anti-inflammatory urinary cytokines are useful in the diagnostic evaluation of risk of sepsis in term neonates. Our objective was to conduct a pilot prospective hospital-based longitudinal observational study of term neonates and test biomarkers for quantification and qualification of urinary cytokine values in those neonates at risk of early neonatal sepsis.</p>
</sec>
<sec id="section2-0009922813482751" sec-type="methods">
<title>Methods</title>
<sec id="section3-0009922813482751">
<title>Study Population</title>
<p>This prospective, hospital-based longitudinal study was approved by the New York University (NYU)/Bellevue Institutional Review Board. A total of 30 full-term neonates born at NYU Tisch Hospital and Bellevue Hospital Center were enrolled in the study during the time period March 2010 to November 2010. The neonates were grouped into 2: (1) the test group, which included neonates admitted to the NICU (neonatal intensive care unit) with a diagnosis of presumed sepsis, and (2) the control group consisting of healthy neonates admitted to the newborn nursery.</p>
</sec>
<sec id="section4-0009922813482751">
<title>Characteristics of the Test Group</title>
<p>All neonates with a maternal history of chorioamnionitis and with or without clinical signs and symptoms of infection were included in the test group. Maternal chorioamnionitis was defined by using any of the following 7 variables: (1) intrapartum fever of &gt;38°C, (2) elevated maternal white blood cell counts of &gt;15 000/mL, (3) maternal heart rate &gt;100 beats/min, (4) fetal heart rate &gt;160 beats/min, (5) uterine tenderness, (6) foul-smelling amniotic fluid or vaginal discharge, and (7) prolonged rupture of membranes for more than 18 hours.<sup><xref ref-type="bibr" rid="bibr20-0009922813482751">20</xref></sup></p>
<p>Maternal variables analyzed were the following: age at the time of delivery, race (black, white, Hispanic, or other), parity (1 or more), cesarean section versus vaginal delivery, smoking status, maternal chorioamnionitis, maternal illness such as gestational diabetes and preeclampsia, and maternal medications before and during pregnancy, including intrapartum antibiotics.</p>
<p>Neonatal symptomatology included the following: respiratory symptoms, such as apnea, tachypnea, difficulty breathing, and desaturation; cardiovascular instability, such as cyanosis, tachycardia, or bradycardia; perfusion deficit or shock; and other signs, such as irritability, lethargy, hypotonia and seizures, abdominal distention, vomiting, dietary intolerance, gastric residue, hepatomegaly, idiopathic jaundice, thermal instability, petechiae or purpura, and a general poor appearance.<sup><xref ref-type="bibr" rid="bibr21-0009922813482751">21</xref>,<xref ref-type="bibr" rid="bibr22-0009922813482751">22</xref></sup> The exclusion criteria were chromosomal anomalies, surgical cases, and congenital heart diseases. Neonates in the control group had normal physical examination findings and were matched as far as possible in demographic characteristics to those in the test group.</p>
</sec>
<sec id="section5-0009922813482751">
<title>Data Collection</title>
<p>After obtaining written, informed consent, we collected demographic and clinical information through maternal interviews and medical chart reviews. Chart reviews were conducted by using a standardized abstraction form that included data on prenatal care, clinical presentation, laboratory data, intrapartum management, pregnancy complications, and birth outcomes.</p>
</sec>
<sec id="section6-0009922813482751">
<title>Biomarker Assays</title>
<p>Urine was collected using urinary bags within the first 48 hours of delivery. The samples were transported on ice and stored at −20°C for not more than 4 hours before aliquoting them and then stored at −80°C in a freezer till the assay was run. All samples were collected within 30 days of assay.</p>
<p>Samples were analyzed simultaneously for 13 immune biomarkers by immunoassay using flowmetric Luminex (200) xMAP technology (Luminex Corp, Austin, TX; Catalog Number: NC004752), chemokine panel 13 Plex (Vendor catalog # MPXHCYTO-60K-13; Fisher Scientific, Hanover Park, IL, and Millipore Corp, Billerica, MA). Biomarkers were quantified by sandwich immunoassays. Each bead set is coated with a capture antibody specific for a specific cytokine. A second biotinylated antibody and streptavidin-phycoerythrin is used to detect the captured cytokine. The Luminex 200 analyzer is a dual-laser, flow-based sorting and detection platform. One laser detects the beads and determines which cytokine is being detected. The second laser determines the magnitude of the phycoerythrin-derived signal, which is proportional to the amount of cytokine bound. The techniques used were described by Skogstrand et al.<sup><xref ref-type="bibr" rid="bibr23-0009922813482751">23</xref></sup></p>
<p>We studied 13 biomarkers in our study and divided them into the above 3 categories as follows: proinflammatory cytokines (IFNγ, TNFα, IP-10, IL-2, IL-6, IL-8, IL-12, and IL-17), anti-inflammatory cytokines (IL-4 and IL-10) and multiple function inflammatory cytokines (IL-1β, MCP-1, and sCD40L).</p>
<p>Millipore (Billerica, MA) chemokine panel 13 kits (Vendor catalog # MPXHCYTO-60K-13) were used for all assays. All samples were run in duplicate and were assayed. The assays were run according to manufacturers’ recommended procedures.</p>
</sec>
<sec id="section7-0009922813482751">
<title>Statistical Analyses</title>
<p>Data were analyzed with Microsoft EXCEL and SPSS 18 (SPSS, Inc, Chicago, IL). Student’s <italic>t</italic> test, the χ<sup>2</sup> test, and Spearman correlation tests were used, as appropriate. <italic>P</italic> values &lt;.05 were considered statistically significant. Results are reported as mean ± standard deviation, percentages, and medians (10th-90th percentile), <italic>r</italic>, and <italic>r</italic><sup>2</sup>.</p>
</sec>
</sec>
<sec id="section8-0009922813482751" sec-type="results">
<title>Results</title>
<p>A total of 30 term neonates were included in the analysis (15 in the test group and 15 controls). Maternal and neonatal demographics are shown in <xref ref-type="table" rid="table1-0009922813482751">Tables 1</xref> and <xref ref-type="table" rid="table2-0009922813482751">2</xref>, respectively. There was no significant difference in the demographic data except for maternal age, intrapartum antibiotics, and length of stay. The mother receiving intrapartum antibiotics and the length of stay were significant as expected because this was the test group (admission to NICU for presumed sepsis).</p>
<table-wrap id="table1-0009922813482751" position="float">
<label>Table 1.</label>
<caption>
<p>Maternal Demographics and Clinical Characteristics of the Study Population.</p>
</caption>
<graphic alternate-form-of="table1-0009922813482751" xlink:href="10.1177_0009922813482751-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Test Group, n = 15</th>
<th align="center">Control Group, n = 15</th>
<th align="center"><italic>P</italic> Value (&lt;.05)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age mean ± SD (years)</td>
<td>29.2 ± 5.8</td>
<td>33.7 ± 5.7</td>
<td>.02<xref ref-type="table-fn" rid="table-fn2-0009922813482751">*</xref></td>
</tr>
<tr>
<td>GBS positive status (%)</td>
<td>26</td>
<td>20</td>
<td>NS</td>
</tr>
<tr>
<td>Rupture of membranes, mean ± SD (hours)</td>
<td>8.5 ± 9.5</td>
<td>4.2 ± 6.7</td>
<td>NS</td>
</tr>
<tr>
<td colspan="3">Race</td>
<td rowspan="5" valign="top">NS</td>
</tr>
<tr>
<td> White</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td> Black</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td> Asian</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td> Hispanic</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Cesarean rates (%)</td>
<td>40</td>
<td>46</td>
<td>NS</td>
</tr>
<tr>
<td>Intrapartum antibiotics (%)</td>
<td>80</td>
<td>0</td>
<td>.007<xref ref-type="table-fn" rid="table-fn2-0009922813482751">*</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0009922813482751">
<p>Abbreviations: SD, standard deviation; GBS, group B <italic>Streptococcus</italic>.</p>
</fn>
<fn id="table-fn2-0009922813482751">
<label>*</label>
<p>Represents statistical significance.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0009922813482751" position="float">
<label>Table 2.</label>
<caption>
<p>Neonatal Demographics.</p>
</caption>
<graphic alternate-form-of="table2-0009922813482751" xlink:href="10.1177_0009922813482751-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Test Group, n = 15</th>
<th align="center">Control Group, n = 15</th>
<th align="center"><italic>P</italic> Value (&lt;.05)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age, mean ± SD (weeks)</td>
<td>39.6 ± 1.4</td>
<td>39.1 ± 0.9</td>
<td>NS</td>
</tr>
<tr>
<td>Birth weight, mean ± SD (grams)</td>
<td>3447 ± 410</td>
<td>3385 ± 407</td>
<td>NS</td>
</tr>
<tr>
<td>Sex (male, %)</td>
<td>66</td>
<td>73</td>
<td>NS</td>
</tr>
<tr>
<td>APGAR score at 5 minutes</td>
<td>8.7 ± 0.5</td>
<td>9 ± 0</td>
<td>NS</td>
</tr>
<tr>
<td>Delivery room resuscitation</td>
<td>3/15 (20%)</td>
<td>0/15 (0%)</td>
<td>NS</td>
</tr>
<tr>
<td>Admission temperature</td>
<td>98.2 ± 0.9</td>
<td>98.3 ± 0.4</td>
<td>NS</td>
</tr>
<tr>
<td>Length of stay</td>
<td>4.6 ± 3.8</td>
<td>2.5 ± 0.6</td>
<td>.02<xref ref-type="table-fn" rid="table-fn4-0009922813482751">*</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0009922813482751">
<p>Abbreviation: SD, standard deviation.</p>
</fn>
<fn id="table-fn4-0009922813482751">
<label>*</label>
<p>Represents statistical significance.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Among the 13 biomarkers we tested, 3 biomarkers with distinct associations were identified. When compared with the control group, IL-8, IP-10, and MCP-1 were all increased in the urine of the test group. Cytokine concentrations in the different urine samples are given as median values and ranges in <xref ref-type="table" rid="table3-0009922813482751">Table 3</xref>. All other cytokines tested were not significantly different between the 2 groups. Data are attached as a supplemental sheet for all the cytokines tested, including IFNγ, TNFα, IL-2, IL-4, IL-6, IL-10, IL-12, IL-17, IL-1β, and sCD40L.</p>
<table-wrap id="table3-0009922813482751" position="float">
<label>Table 3.</label>
<caption>
<p>Cytokine Results.</p>
</caption>
<graphic alternate-form-of="table3-0009922813482751" xlink:href="10.1177_0009922813482751-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Test Group, n = 15</th>
<th align="center">Control Group, n = 15</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">IL-8 (pg/mL)</td>
<td>.004<xref ref-type="table-fn" rid="table-fn6-0009922813482751">*</xref></td>
</tr>
<tr>
<td> Mean ± SD</td>
<td>24.9 ± 12.1</td>
<td>13.2 ± 11</td>
<td/></tr>
<tr>
<td> Median</td>
<td>22.8 (9.02-56.1)</td>
<td>10.9 (1.54-35)</td>
<td/></tr>
<tr>
<td colspan="3">IP-10 (pg/mL)</td>
<td>.007<xref ref-type="table-fn" rid="table-fn6-0009922813482751">*</xref></td>
</tr>
<tr>
<td> Mean ± SD</td>
<td>134.2 ± 161</td>
<td>16.7 ± 29.7</td>
<td/></tr>
<tr>
<td> Median</td>
<td>58.9 (0-490)</td>
<td>6.3 (0-112)</td>
<td/></tr>
<tr>
<td colspan="3">MCP-1 (pg/mL)</td>
<td>.02<xref ref-type="table-fn" rid="table-fn6-0009922813482751">*</xref></td>
</tr>
<tr>
<td> Mean ± SD</td>
<td>1662.6 ± 1823.8</td>
<td>632.6 ± 495</td>
<td/></tr>
<tr>
<td> Median</td>
<td>874 (190-5330)</td>
<td>416 (163-1670)</td>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0009922813482751">
<p>Abbreviations: SD, standard deviation; IL, interleukin; IP, inducible protein; MCP, monocyte chemoattractant protein.</p>
</fn>
<fn id="table-fn6-0009922813482751">
<label>*</label>
<p>Represents statistical significance.</p></fn>
</table-wrap-foot>
</table-wrap>
<sec id="section9-0009922813482751">
<title>Subgroup Analyses</title>
<p>In the 15 test patients we tested, the first 8 patients were admitted for presumed sepsis secondary to maternal chorioamnionitis, the next 4 infants were admitted because of respiratory distress and sepsis evaluation, and the last 3 had both indications of maternal chorioamnionitis and were symptomatic on admission. The cytokine levels in urine had a tendency to correlate more with symptomatic infants with risk factors for sepsis. In the 15 control infants, the first 10 patients had no risk factors for sepsis; the last 5 had risk factors for sepsis but did not meet criteria for NICU admission.</p>
<p>So when IL-8 levels were compared between the stratified groups within the test group, the first 8 patients were admitted for maternal reasons alone and the next 4 patients had symptoms that may or may not have been sepsis related and hence the responses to increases were not marked. When we specifically compare the combined effect of having maternal risk factors and symptoms, the biomarkers tested become significant.</p>
<p>To show this effect, we compared IL-8 with the I/T ratio (immature to total neutrophil) in the test group. We chose the I/T ratio instead of the WBC count because this has a higher sensitivity for diagnosing bacteremia in a neonate.<sup><xref ref-type="bibr" rid="bibr24-0009922813482751">24</xref></sup> This showed a positive correlation with IL-8, increasing with increasing I/T ratio, as shown in <xref ref-type="fig" rid="fig1-0009922813482751">Figure 1</xref>. IP-10 and MCP-1 (<xref ref-type="fig" rid="fig2-0009922813482751">Figure 2</xref>) also show similar trends. This shows that these markers can be used as adjuncts in diagnosing sepsis.</p>
<fig id="fig1-0009922813482751" position="float">
<label>Figure 1.</label>
<caption>
<p>IL-8 versus I/T ratio.</p>
<p>Abbreviations: IL, interleukin; I/T, immature to total neutrophil.</p>
</caption>
<graphic xlink:href="10.1177_0009922813482751-fig1.tif"/>
</fig>
<fig id="fig2-0009922813482751" position="float">
<label>Figure 2.</label>
<caption>
<p>MCP-1 versus I/T ratio.</p>
<p>Abbreviations: MCP, monocyte chemoattractant protein; I/T, immature to total neutrophil.</p>
</caption>
<graphic xlink:href="10.1177_0009922813482751-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section10-0009922813482751" sec-type="discussion">
<title>Discussion</title>
<p>We believe that this is the first study to demonstrate that these proinflammatory cytokines can be isolated in urine. Neonatal sepsis is a major issue in NICUs all over the world. Early diagnosis and treatment of neonatal sepsis are very important to prevent mortality and morbidity. Clinical signs and symptoms are usually nonspecific and may be difficult to distinguish. Laboratory studies, such as white blood cell count and IL and C-reactive protein (CRP) levels may be used to diagnose sepsis.<sup><xref ref-type="bibr" rid="bibr25-0009922813482751">25</xref></sup> Although blood culture remains the gold standard, it can have false-negative results; also, culture results are not available before 48 hours, and culture positivity rates range from 25% to 54%<sup><xref ref-type="bibr" rid="bibr9-0009922813482751">9</xref></sup> versus 8% to 73% in various studies.<sup><xref ref-type="bibr" rid="bibr26-0009922813482751">26</xref></sup></p>
<p>When the high mortality and serious morbidity associated with neonatal sepsis are taken into consideration, it is desirable for the ideal diagnostic marker to have about 100% sensitivity and negative predictive value. To minimize the unnecessary use of antibiotics in false-positive cases, a competent diagnostic marker also needs to have reasonably high specificity and a good positive predictive value, preferably better than 85%.<sup><xref ref-type="bibr" rid="bibr27-0009922813482751">27</xref></sup> In the past 2 decades, researchers have investigated various acute-phase reactants, including cytokines, adhesion molecules, and cell surface markers, for the early and reliable diagnosis of neonatal sepsis.<sup><xref ref-type="bibr" rid="bibr26-0009922813482751">26</xref><xref ref-type="bibr" rid="bibr27-0009922813482751"/><xref ref-type="bibr" rid="bibr28-0009922813482751"/><xref ref-type="bibr" rid="bibr29-0009922813482751"/>-<xref ref-type="bibr" rid="bibr30-0009922813482751">30</xref></sup></p>
<p>Today, CRP, TNFα, and IL-8 may be useful in the detection of infection, but they are not yet routinely used worldwide<sup><xref ref-type="bibr" rid="bibr27-0009922813482751">27</xref><xref ref-type="bibr" rid="bibr28-0009922813482751"/><xref ref-type="bibr" rid="bibr29-0009922813482751"/><xref ref-type="bibr" rid="bibr30-0009922813482751"/><xref ref-type="bibr" rid="bibr31-0009922813482751"/>-<xref ref-type="bibr" rid="bibr32-0009922813482751">32</xref></sup> because it is another invasive test in a neonate. Testing and qualifying new biomarkers in urine opens a new era of noninvasive testing, which can be used as an adjunct to the current sepsis protocols. In our study, we saw increases in IL-8, MCP-1, and IP-10 that are easily quantifiable. Our study is a pilot study, but if done on a larger sample size, it will maximize sensitivity and negative predictive value, so that antibiotics can be discontinued early.</p>
<p>IL-6 as an early biomarker in the diagnosis of sepsis has been studied extensively, but IL-6 has a short half-life, and circulating levels decrease precipitously back to the baseline noninfectious state within 24 hours of appropriate treatment in serum samples. As the urine of most neonates was collected after the initiation of antibiotics, the levels of IL-6 were not detectable in our study. Usually, a rising IL-6 precedes a high CRP; in our study, we did not compare our cytokine levels to CRP because all neonates did not have a CRP drawn as a part of the sepsis evaluation.</p>
<p>Because this is a pilot study, there are a few limitations of the study. First, the urine samples were not quantified based on the neonate’s renal function like serum BUN or creatinine levels. The effects of not quantifying are not known at this time. Also, none of the neonates in the test group had a positive blood culture. All specimens were bagged specimens, which is important for our study because we are trying to find a noninvasive method to add to the current sepsis protocols. We did not catheterize any of our infants to eliminate confounding results of elevated cytokines that could be a result of the trauma induced by catheterization itself. Because this a pilot project, future directions for this research would include increasing sample size and quantifying urine with renal function of the neonate and to test these cytokines in neonates with positive blood cultures.</p>
</sec>
<sec id="section11-0009922813482751" sec-type="conclusions">
<title>Conclusions</title>
<p>We conclude that urinary biomarkers IL-8, IP-10, and MCP-1 are proinflammatory cytokines that are increased in infectious inflammatory response in the neonate. All 3 cytokines showed good correlation with increasing serum I/T ratio. Therefore, urinary IL-8, IP-10, and MCP-1 may be useful biomarkers in the early evaluation of neonates at risk for sepsis when coupled with current sepsis evaluation methods.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other">
<label>Authors Note</label>
<p>The * represents statistical significance in the abstract and in the table.</p>
</fn>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by the NIH CTSI (Clinical Translational Science Institute) Grant: NIH/NCRR 1 U54 RR024386-01A1 and the Jack Cary Eichenbaum Foundation at NYU Langone Medical Center Division of Neonatology Scholarship Fund. We would also like to thank Mr Frank Martinuik and Maryann Huie for technical support and use of their laboratory.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0009922813482751">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quie</surname><given-names>PG</given-names></name>
</person-group>. <article-title>Neonatal septicemia</article-title>. <source>Antibiot Chemother</source>. <year>1976</year>;<volume>21</volume>:<fpage>128</fpage>.</citation>
</ref>
<ref id="bibr2-0009922813482751">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Short</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Guide to a systematic physical assessment in the infant with suspected infection and or sepsis</article-title>. <source>Adv Neonatal Care</source>. <year>2004</year>;<volume>4</volume>:<fpage>141</fpage>-<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr3-0009922813482751">
<label>3.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Anderson-Berry</surname><given-names>AL</given-names></name>
<name><surname>Bellig</surname><given-names>LL</given-names></name>
</person-group>. <article-title>B. Neonatal sepsis</article-title>. <ext-link ext-link-type="uri" xlink:href="http://emedicine.medscape.com/article/978352-overview">http://emedicine.medscape.com/article/978352-overview</ext-link>. <access-date>Accessed March 15, 2013</access-date>.</citation>
</ref>
<ref id="bibr4-0009922813482751">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klinger</surname><given-names>G</given-names></name>
<name><surname>Levy</surname><given-names>I</given-names></name>
<name><surname>Sirota</surname><given-names>L</given-names></name>
<name><surname>Boyko</surname><given-names>V</given-names></name>
<name><surname>Reichman</surname><given-names>B</given-names></name>
<name><surname>Lerner-Geva</surname><given-names>L</given-names></name>
</person-group>. <article-title>Epidemiology and risk factors for early onset sepsis among very-low-birthweight infants</article-title>. <source>Am J Obstet Gynecol</source>. <year>2009</year>;<volume>201</volume>:<fpage>38.e1</fpage>-<lpage>38.e6</lpage>.</citation>
</ref>
<ref id="bibr5-0009922813482751">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van den Hoogen</surname><given-names>A</given-names></name>
<name><surname>Gerards</surname><given-names>LJ</given-names></name>
<name><surname>Verboon-Maciolek</surname><given-names>MA</given-names></name>
<name><surname>Fleer</surname><given-names>A</given-names></name>
<name><surname>Krediet</surname><given-names>TG</given-names></name>
</person-group>. <article-title>Long-term trends in the epidemiology of neonatal sepsis and antibiotic susceptibility of causative agents</article-title>. <source>Neonatology</source>. <year>2009</year>;<volume>97</volume>:<fpage>22</fpage>-<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr6-0009922813482751">
<label>6.</label>
<citation citation-type="book">
<collab>American Academy of Pediatrics (AAP)</collab>. <source>Red Book 2003</source>. <edition>26th ed</edition>. <publisher-loc>Elk Grove, IL</publisher-loc>: <publisher-name>AAP</publisher-name>; <year>2003</year>:<fpage>117</fpage>-<lpage>123</lpage>, <fpage>237</fpage>-<lpage>243</lpage>, <fpage>561</fpage>-<lpage>573</lpage>, <fpage>584</fpage>-<lpage>591</lpage>.</citation>
</ref>
<ref id="bibr7-0009922813482751">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schrag</surname><given-names>S</given-names></name>
<name><surname>Gorwitz</surname><given-names>R</given-names></name>
<name><surname>Fultz-Butts</surname><given-names>K</given-names></name>
<name><surname>Schuchat</surname><given-names>A</given-names></name>
</person-group>. <article-title>Prevention of perinatal group B streptococcal disease: revised guidelines from CDC</article-title>. <source>MMWR Recomm Rep</source>. <year>2002</year>;<volume>51</volume>(<issue>RR-11</issue>):<fpage>1</fpage>-<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr8-0009922813482751">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arnon</surname><given-names>S</given-names></name>
<name><surname>Litmanovitz</surname><given-names>I</given-names></name>
</person-group>. <article-title>Diagnostic tests in neonatal sepsis</article-title>. <source>Curr Opin Infect Dis</source>. <year>2008</year>;<volume>21</volume>:<fpage>223</fpage>-<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr9-0009922813482751">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>PC</given-names></name>
</person-group>. <article-title>Diagnostic markers of infection in neonates</article-title>. <source>Arch Dis Child Fetal Neonatal Ed</source>. <year>2004</year>;<volume>89</volume>:<fpage>F229</fpage>-<lpage>F235</lpage>.</citation>
</ref>
<ref id="bibr10-0009922813482751">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lam</surname><given-names>HS</given-names></name>
<name><surname>Ng</surname><given-names>PC</given-names></name>
</person-group>. <article-title>Biochemical markers of neonatal sepsis</article-title>. <source>Pathology</source>. <year>2008</year>;<volume>40</volume>:<fpage>141</fpage>-<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr11-0009922813482751">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Russell</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Management of sepsis</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>355</volume>:<fpage>1699</fpage>-<lpage>1713</lpage>.</citation>
</ref>
<ref id="bibr12-0009922813482751">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stoll</surname><given-names>BJ</given-names></name>
<name><surname>Hansen</surname><given-names>NI</given-names></name>
<name><surname>Adams-Chapman</surname><given-names>I</given-names></name><etal/>
</person-group>. <article-title>Neurodevelopmental and growth impairment among extremely low-birth- weight infants with neonatal infection</article-title>. <source>JAMA</source>. <year>2004</year>;<volume>292</volume>:<fpage>2357</fpage>-<lpage>2365</lpage>.</citation>
</ref>
<ref id="bibr13-0009922813482751">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krueger</surname><given-names>M</given-names></name>
<name><surname>Nauck</surname><given-names>MS</given-names></name>
<name><surname>Sang</surname><given-names>S</given-names></name>
<name><surname>Hentschel</surname><given-names>R</given-names></name>
<name><surname>Wieland</surname><given-names>H</given-names></name>
<name><surname>Berner</surname><given-names>R</given-names></name>
</person-group>. <article-title>Cord blood levels of interleukin-6 and interleukin-8 for the immediate diagnosis of early-onset infection in premature infants</article-title>. <source>Biol Neonate</source>. <year>2001</year>;<volume>80</volume>:<fpage>118</fpage>-<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr14-0009922813482751">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoon</surname><given-names>BH</given-names></name>
<name><surname>Romero</surname><given-names>R</given-names></name>
<name><surname>Park</surname><given-names>JS</given-names></name><etal/>
</person-group>. <article-title>The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis</article-title>. <source>Am J Obstet Gynecol</source>. <year>2000</year>;<volume>83</volume>:<fpage>1124</fpage>-<lpage>1129</lpage>.</citation>
</ref>
<ref id="bibr15-0009922813482751">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hermansen</surname><given-names>MC</given-names></name>
<name><surname>Hermansen</surname><given-names>MG</given-names></name>
</person-group>. <article-title>Perinatal infections and cerebral palsy</article-title>. <source>Clin Perinatol</source>. <year>2006</year>;<volume>33</volume>:<fpage>315</fpage>-<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr16-0009922813482751">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dammann</surname><given-names>O</given-names></name>
<name><surname>Leviton</surname><given-names>A</given-names></name>
</person-group>. <article-title>Inflammation, brain damage and visual dysfunction in preterm infants</article-title>. <source>Semin Fetal Neonatal Med</source>. <year>2006</year>;<volume>11</volume>:<fpage>363</fpage>-<lpage>368</lpage>.</citation>
</ref>
<ref id="bibr17-0009922813482751">
<label>17.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>La Pine</surname><given-names>TR</given-names></name>
<name><surname>Hill</surname><given-names>HR</given-names></name>
</person-group>. <article-title>Host defense mechanisms against bacteria</article-title>. In: <person-group person-group-type="editor">
<name><surname>Polin</surname><given-names>RA</given-names></name>
<name><surname>Fox</surname><given-names>WW</given-names></name>
<name><surname>Abman</surname><given-names>SH</given-names></name>
</person-group>, eds. <source>Fetal and Neonatal Physiology</source>. <edition>3rd ed</edition>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Saunders</publisher-name>; <year>2004</year>:<fpage>1475</fpage>-<lpage>1486</lpage>.</citation>
</ref>
<ref id="bibr18-0009922813482751">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Herman</surname><given-names>MP</given-names></name>
<name><surname>Svatek</surname><given-names>RS</given-names></name>
<name><surname>Lotan</surname><given-names>Y</given-names></name>
<name><surname>Karakiewizc</surname><given-names>PI</given-names></name>
<name><surname>Shariat</surname><given-names>SF</given-names></name>
</person-group>. <article-title>Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer</article-title>. <source>Minerva Urol Nefrol</source>. <year>2008</year>;<volume>60</volume>:<fpage>217</fpage>-<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr19-0009922813482751">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rivera</surname><given-names>S</given-names></name>
<name><surname>Sattler</surname><given-names>FR</given-names></name>
<name><surname>Boyd</surname><given-names>H</given-names></name>
<name><surname>Auffenberg</surname><given-names>T</given-names></name>
<name><surname>Nakao</surname><given-names>S</given-names></name>
<name><surname>Moldawer</surname><given-names>LL</given-names></name>
</person-group>. <article-title>Urinary cytokines for assessing inflammation in HIV-associated wasting</article-title>. <source>Cytokine</source>. <year>2001</year>;<volume>13</volume>: <fpage>305</fpage>-<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr20-0009922813482751">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gibbs</surname><given-names>RS</given-names></name>
<name><surname>Blanco</surname><given-names>JD</given-names></name>
<name><surname>St Clair</surname><given-names>PJ</given-names></name>
<name><surname>Castaneda</surname><given-names>YS</given-names></name>
</person-group>. <article-title>Quantitative bacteriology of amniotic fluid from women with clinical intraamniotic infection at term</article-title>. <source>J Infect Dis</source>. <year>1982</year>;<volume>145</volume>:<fpage>1</fpage>-<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr21-0009922813482751">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bone</surname><given-names>RC</given-names></name>
</person-group>. <article-title>Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions</article-title>. <source>Ann Intern Med</source>. <year>1991</year>;<volume>114</volume>:<fpage>332</fpage>-<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr22-0009922813482751">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silveira</surname><given-names>RC</given-names></name>
<name><surname>Procianoy</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Evaluation of interleukin-6, tumour necrosis factor alpha and interleukin-1beta for early diagnosis of neonatal sepsis</article-title>. <source>Acta Paediatr</source>. <year>1999</year>;<volume>88</volume>:<fpage>647</fpage>-<lpage>650</lpage>.</citation>
</ref>
<ref id="bibr23-0009922813482751">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skogstrand</surname><given-names>K</given-names></name>
<name><surname>Thorsen</surname><given-names>P</given-names></name>
<name><surname>Norgaard-Pedersen</surname><given-names>B</given-names></name>
<name><surname>Schendel</surname><given-names>DE</given-names></name>
<name><surname>Sorensen</surname><given-names>LC</given-names></name>
<name><surname>Hougaard</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology</article-title>. <source>Clin Chem</source>. <year>2005</year>;<volume>51</volume>:<fpage>1854</fpage>-<lpage>1866</lpage>.</citation>
</ref>
<ref id="bibr24-0009922813482751">
<label>24.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Behrman</surname><given-names>RE</given-names></name>
<name><surname>Kleigman</surname><given-names>RM</given-names></name>
<name><surname>Jenson</surname><given-names>HB</given-names></name>
</person-group>, eds. <source>Nelson Textbook of Pediatrics</source>. <edition>18th ed</edition>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Saunders Elsevier</publisher-name>.</citation>
</ref>
<ref id="bibr25-0009922813482751">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gladstone</surname><given-names>IM</given-names></name>
<name><surname>Ehrenkranz</surname><given-names>RA</given-names></name>
<name><surname>Edberg</surname><given-names>SC</given-names></name>
<name><surname>Baltimore</surname><given-names>RS</given-names></name>
</person-group>. <article-title>A ten year review of neonatal sepsis and comparison with the previous fifty-year experience</article-title>. <source>Pediatr Infect Dis J</source>. <year>1990</year>;<volume>9</volume>:<fpage>819</fpage>-<lpage>825</lpage>.</citation>
</ref>
<ref id="bibr26-0009922813482751">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mishra</surname><given-names>UK</given-names></name>
<name><surname>Jacobs</surname><given-names>SE</given-names></name>
<name><surname>Doyle</surname><given-names>LW</given-names></name>
<name><surname>Garland</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Newer approaches to the diagnosis of early onset neonatal sepsis</article-title>. <source>Arch Dis Child Fetal Neonatal Ed</source>. <year>2006</year>;<volume>91</volume>:<fpage>F208</fpage>-<lpage>F212</lpage>.</citation>
</ref>
<ref id="bibr27-0009922813482751">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>PC</given-names></name>
<name><surname>Li</surname><given-names>K</given-names></name>
<name><surname>Wong</surname><given-names>RP</given-names></name>
<name><surname>Chui</surname><given-names>KM</given-names></name>
<name><surname>Wong</surname><given-names>E</given-names></name>
<name><surname>Fok</surname><given-names>TF</given-names></name>
</person-group>. <article-title>Neutrophil CD64 expression: a sensitive diagnostic marker for late-onset nosocomial infection in very low birthweight infants</article-title>. <source>Pediatr Res</source>. <year>2002</year>;<volume>51</volume>:<fpage>296</fpage>-<lpage>303</lpage>.</citation>
</ref>
<ref id="bibr28-0009922813482751">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehr</surname><given-names>S</given-names></name>
<name><surname>Doyle</surname><given-names>LW</given-names></name>
</person-group>. <article-title>Cytokines as markers of bacterial sepsis in newborn infants: a review</article-title>. <source>Pediatr Infect Dis J</source>. <year>2000</year>;<volume>19</volume>:<fpage>879</fpage>-<lpage>887</lpage>.</citation>
</ref>
<ref id="bibr29-0009922813482751">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Onal</surname><given-names>EE</given-names></name>
<name><surname>Kitapçi</surname><given-names>F</given-names></name>
<name><surname>Dilmen</surname><given-names>U</given-names></name>
<name><surname>Adam</surname><given-names>B</given-names></name>
</person-group>. <article-title>Interleukin-6 concentrations in neonatal sepsis</article-title>. <source>Lancet</source>. <year>1999</year>;<volume>353</volume>:<fpage>239</fpage>-<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr30-0009922813482751">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ng</surname><given-names>PC</given-names></name>
<name><surname>Cheng</surname><given-names>SH</given-names></name>
<name><surname>Chui</surname><given-names>KM</given-names></name><etal/>
</person-group>. <article-title>Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecule, and C-reactive protein in preterm very low birthweight infants</article-title>. <source>Arch Dis Child Fetal Neonatal Ed</source>. <year>1997</year>;<volume>77</volume>:<fpage>F221</fpage>-<lpage>F227</lpage>.</citation>
</ref>
<ref id="bibr31-0009922813482751">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mathai</surname><given-names>E</given-names></name>
<name><surname>Christopher</surname><given-names>U</given-names></name>
<name><surname>Mathai</surname><given-names>M</given-names></name>
<name><surname>Jana</surname><given-names>AK</given-names></name>
<name><surname>Rose</surname><given-names>D</given-names></name>
<name><surname>Bergstrom</surname><given-names>S</given-names></name>
</person-group>. <article-title>Is C-reactive protein level useful in differentiating infected from uninfected neonates among those at risk of infection?</article-title> <source>Indian Pediatr</source>. <year>2004</year>;<volume>41</volume>: <fpage>895</fpage>-<lpage>900</lpage>.</citation>
</ref>
<ref id="bibr32-0009922813482751">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benitz</surname><given-names>WE</given-names></name>
<name><surname>Han</surname><given-names>MY</given-names></name>
<name><surname>Madan</surname><given-names>A</given-names></name>
<name><surname>Ramachandra</surname><given-names>P</given-names></name>
</person-group>. <article-title>Serial serum C-reactive protein levels in the diagnosis of neonatal infection</article-title>. <source>Pediatrics</source>. <year>1998</year>;<volume>102</volume>:<fpage>E41</fpage>.</citation>
</ref>
</ref-list>
</back>
</article>